After the FDA approved cenobamate (Xcopri; SK Life Science) for the treatment of partial-onset seizures in adults, SK Life Sciences announced that it is expected to become available in Q2 2020 following a scheduling review by the DEA. These long-term safety data were collected from the ongoing open-label extension study of phase 2, double-blind, 12-week, placebo-controlled trial (NCT01397968).1
One of the physicians who has had an early exposure to this therapy in the treatment of patients with epilepsy is Jacqueline A. French, MD, professor of neurology, NYU Langone Medical Center. Having been involved in the clinical development of the sodium channel antagonist, she was able to share her experiences with NeurologyLive at the 73rd annual meeting of the American Epilepsy Society (AES), December 6-10, 2019, in Baltimore, Maryland.
French discussed her expectations for how this therapy will be utilized by physicians once it hits the market, and shared her perspective on what its possible impact might be with certain patients who are unable to achieve seizure control.
